Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$1.5B
30M shares
52-week range
$31.44 – $56.64
73% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NYSE
CS
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
www.conmed.comNo one on the platform currently holds CNMD.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-09-30 | 76,581 | $5.5M |
| Bridgewater Associatesas of 2025-09-30 | 5,933 | $279.0K |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-09-15 | $0.2000 | 2025-10-03 |
| 2025-06-13 | $0.2000 | 2025-07-03 |
| 2025-03-14 | $0.2000 | 2025-04-04 |
| 2024-12-20 | $0.2000 | 2025-01-03 |
| 2024-09-16 | $0.2000 | 2024-10-04 |
| 2024-06-14 | $0.2000 | 2024-07-05 |
| 2024-03-14 | $0.2000 | 2024-04-05 |
| 2023-12-15 | $0.2000 | 2024-01-05 |
| 2023-09-14 | $0.2000 | 2023-10-05 |
No one on the platform has traded CNMD yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Wall St is expecting 1.00 EPS for $CNMD Q3 [Reporting 10/28 AMC] http://www.estimize.com/intro/cnmd?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$CNMD Conmed raises FY26 EPS view to $4.48-$4.60 from $4.30-$4.45, consensus $4.34 Raises FY26 revenue view to $1.358B-$1.373B from $1.35B-$1.375B, consensus $1.36B.
View on StockTwits ↗$CNMD Conmed reports Q2 adjusted EPS $1.38, consensus $1.11 Reports Q2 rervenue $343.5M, consensus $337.54M. "We delivered a strong second quarter, with organic constant currency net sales growth and adjusted diluted EPS that exceeded our stated expectations," said Patrick J. Beyer, CONMED's President and Chief Executive Officer. "Our net sales performance on an organic constant currency basis reflected year-over-year growth across both our Orthopedic Surgery and General Surgery product lines, as our team continued to advance our key growth platforms: AirSeal, Buffalo Filter, and BioBrace. In tandem, we made meaningful progress on several strategic priorities during the quarter, including: completing the strategic exits of our gastroenterology product offerings in keeping with our portfolio optimization strategy, refinancing a portion of our debt, and further strengthening our leadership with key appointments to our Board and executive team."
View on StockTwits ↗$CNMD Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.77 up 11.59% YoY • Reported revenue of $343.49M up 0.33% YoY
View on StockTwits ↗🚀 Weekly Results (July 13–17) Strong performance again this week. ⭐ Top Trades: $ZNTL +10.1% $CNMD +9.1% $DINO +8.8% $TRVI +8.7% $ANGO +7.4% 📊 Consistent gains across the board. Discipline. Strategy. Results.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.4B | -0.2% | $4.54 | $4.50–$4.57 | 11.0× | 4 |
| 2027 | $1.4B | +5.0% | $4.78 | $4.64–$4.88 | 10.4× | 4 |
| 2028 | $1.5B | +5.4% | $5.39 | $5.35–$5.43 | 9.2× | 1 |
| 2029 | $1.6B | +5.2% | $6.11 | $6.06–$6.16 | 8.2× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $1.11 | $1.38 | +24.3% |
| 2026-04-29 | $0.82 | $0.89 | +8.5% |
| 2026-01-28 | $1.32 | $1.43 | +8.3% |
| 2025-11-05 | $1.05 | $1.08 | +2.9% |
| 2025-07-30 | $1.13 | $1.15 | +1.8% |
| 2025-04-30 | $0.81 | $0.95 | +17.3% |
| 2025-02-05 | $1.20 | $1.34 | +11.7% |
| 2024-10-30 | $0.99 |
| $1.05 |
| +6.1% |
| $874M |
| — |
| KMTSKestra Medical Technologies, Ltd. | $27.74 | -0.93% | $1.6B | — |
| NEOGNeogen Corporation | $11.89 | +3.75% | $2.6B | — |
Source: Financial Modeling Prep · peers by sector/industry